This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Biotinylated Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His,Avitag™&Tag Free
catalog :
IT7-H82W9
quantity :
200 ug, 25 ug
price :
1380 USD, 350 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
IT7-H82W9
product name :
Biotinylated Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His,Avitag™&Tag Free
quantity :
200 ug, 25 ug
price :
1380 USD, 350 USD
quantity & price :
$350/25ug,$1380/200ug
target :
Integrin alpha 4 beta 7
host species :
Human
By Tag :
His Tag & Avi Tag
Research :
For Research Use Only
Source :
Biotinylated Human ITGA4&ITGB7 Heterodimer Protein, His,Avitag&Tag Free (IT7-H82W9) is expressed from human 293 cells (HEK293). It contains AA Tyr 34 - Thr 977 (ITGA4) & Glu 20 - His 723 (ITGB7) (Accession # P13612-1 (ITGA4) & P26010-1 (ITGB7)).
SDS-PAGE Remark(R&NR) :
Biotinylated Human ITGA4&ITGB7 Heterodimer Protein, His,Avitag&Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than .
Formulation :
Please contact us for detailed information. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Integrin alpha 4 beta 7 is an integrin family adhesion receptor that shares subunits with alpha 4 beta 1 (VLA4) and the E-Cadherin receptor, alpha E beta 7 . Integrin alpha 4 beta 7, which is critical for homing to intestinal mucosa, is induced during T cell activation in Peyer’s patches or mesenteric lymph nodes.Its expression requires signals from local dendritic and stromal cells, including secreted retinoic acid. The HIV-1 envelope protein gp120 binds to the active form of Integrin alpha 4 beta 7, and this may or may not account for the concentration of HIV-1 virus in the gut-associated lymphoid tissue (GALT). Integrin alpha 4 beta 7 may also be involved in lymphocyte trafficking in acute intestinal graft vs. host disease (GVHD).
References :
(1) Arthos Jet, et al., 2008, Nat Immunol., 9(3), 301-9.
(2) Monteiro P, et al., 2011, J Immunol.l., 186(8), 4618-30.
(3) Chen YB, et al., 2013, Bone Marrow Transplant., 48(4), 598-603.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments